Avrobio Receives Seed Financing Round

  • Feed Type
  • Date
  • Company Name
  • Mailing Address
    400 Technology Square 10th Floor Cambridge, MA 02139 USA
  • Company Description
    AVROBIO is a clinical stage company developing step-change cell and gene therapies targeting cancer and rare disease. The catalyst for creating AVROBIO is to accelerate scientific breakthroughs related to the convergence of cell and gene therapies.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
  • Proceeds Purposes
    The company will use the funds to accelerate development of two novel cell and gene therapies pioneered within the labs of Dr. Christopher Paige and Dr. Jeffrey Medin (now at the Medical College of Wisconsin) at the University Health Network (UHN) in Toronto, ON. Phase 1 programs will be in the clinic by early to mid-2016 in both acute myeloid leukemia (AML) and Fabry disease. The company will simultaneously work to expand its proprietary cell and gene therapy platform to treat additional indications.
  • M&A Terms
  • Venture Investor

Trending on Xconomy